23andMe Holding Co.: directors' dealings · United States · SEC (Form 4)

About 23andMe Holding Co.

23andMe Holding Co. is a United States-based consumer genetics and biotechnology company that was historically listed on the Nasdaq before its stock was suspended and the company moved through a bankruptcy-driven restructuring in 2025. The company was founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza, and is headquartered in Sunnyvale, California. Its core investment thesis has centered on using large-scale human genetic data to serve consumers while also creating a research engine that can generate biological insights and support drug discovery. Operationally, 23andMe built its brand around direct-to-consumer DNA testing. Its flagship Personal Genome Service has focused on ancestry, DNA relatives, and selected health and wellness reports. The company’s commercial model combines consumer genomics with research participation, allowing customers to opt in to contribute their genetic and phenotypic data to research studies. That consented data asset is one of 23andMe’s key competitive differentiators: it has helped the company build a sizable proprietary dataset and a recognized platform for genetically informed research, which is difficult for new entrants to replicate quickly. The company also developed a therapeutics business intended to translate human genetics into drug target identification and early-stage pipeline opportunities. This was designed as a long-duration value creation lever, complementing the consumer business with a higher-upside but more uncertain biotech-like opportunity set. In addition, 23andMe operated telehealth-related offerings through Lemonaid Health, broadening its footprint into consumer healthcare services. However, in 2025 those assets became part of a broader sale process and were no longer the center of the story from a public-market perspective. For investors, the most important recent developments are strategic rather than purely operational. In March 2025, 23andMe initiated voluntary Chapter 11 proceedings in the United States. The company then announced plans to delist from Nasdaq and deregister with the SEC, signaling the end of its life as a conventional listed equity story. In June 2025, 23andMe announced a definitive agreement to sell substantially all of its assets to TTAM Research Institute, followed by court approval and later completion of the transaction in July 2025. As a result, the stock should be viewed through a distressed-restructuring lens rather than a normal growth-equity lens. Even so, 23andMe remains a notable U.S. franchise in consumer genetics, with historical relevance in ancestry testing, genetic health reporting, and research-enabled precision medicine.